HER2-amplified/overexpressed ILCs usually have higher tumor stage, more frequent positive nodal status, more distant metastases, and higher histological grade, and were more often HR negative when compared to HER2 negative ILCs [38,62,94,95,96,97,98,99]. Here, ERBB2 is linked to neoplasm.